Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
LUPIN
Ms. Vinita D. Gupta · Mumbai, India · 26,021 employees
₹2,447.00
▲+2.14%Lupin, a leading Indian pharmaceutical company, is trading near its 52-week high on strong revenue growth and expanding market share.
Exchange
NSI
Currency
INR
Day range
₹2,402.00 – ₹2,463.00
52-week range
₹1,836.80 – ₹2,529.50
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis90% confidence
Trading within 10% of the 52-week high, Lupin appears fairly valued, considering the 21.02 P/E and 31.90% revenue growth, but still has room for growth as it continues to expand its market share.
3.3% below the 1-year high · trend up
Hedge-fund memo
Today
2.14% gain, trading in the upper third of its 1-year range, strong institutional backing (34.79%)
This week
Closed near the 52-week high, volume traded higher than its 1-year average
This month
Up 10.4% in the last 30 days, outperforming the industry
Bull thesis
Bear thesis
Hidden risks
Hidden opportunities
News & sentiment
Neutral
24 headlines · 17 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 4 of 4 recent quarters (EPS actual vs. consensus).
34.75 vs 27.92834
24.43% surprise
32.18 vs 27.67825
16.26% surprise
32.28 vs 26.01349
24.09% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| LUPIN | 1.12T | 21.02 | 26.91% | 24.22% | 31.90% |
| SUNPHARMA | 4.77T | 41.59 | 14.72% | 19.23% | 12.80% |
| AUROPHARMA | 915.25B | 26.40 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Competition from established generic pharmaceutical companies
Mitigation: Product diversification and forays into biotechnology
Regulatory challenges in key geographies
Mitigation: Strategic partnerships and investments in emerging markets
Business intelligence
Competitive moat
Lupin's strong global presence, diversified product portfolio, and significant investment in research and development drive its competitive moat.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
No notable recent activity flagged.
Catalyst calendar
Product launches in key markets, further expansion into biotechnology
Thesis builder
Bull case
Strong revenue growth and expanding market share will lead Lupin to reach $2,700 within the next 12-18 months.
Base case
Lupin will reach $2,400, a stable but slower growth trajectory over the next 24-36 months.
Bear case
Increased competition and pricing pressure will result in a decline to $2,000 within the next 12-18 months.
Time horizon
3-5 years
Est. CAGR
12-18%
Entry (qual.)
Buy on dips, targeting a minimum 15% correction from current levels.
Exit (qual.)
Sell 20% above our price target to lock in profits.
Overall conviction 90%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how LUPIN fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain LUPIN for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Watch next
Buy Lupin on dips, targeting a price of $2,700 within the next 12-18 months, driven by growth in the generic and biotechnology segments.
Top Class Actions·8h ago·recall raises safety and liability concerns
MarketsMojo·12h ago·open interest shift may signal hedging
Business Upturn·18h ago·general market mention only
GRDC·22h ago·unrelated agricultural topic
marketscreener.com·1d ago·new US FDA approval expands portfolio
Business Upturn·1d ago·FDA approval broadens anticoagulant offering
Sahi·1d ago·US FDA nod supports generics growth
PR Newswire·1d ago·approval adds injectable diazepam to US sales
The Times of India·1d ago·historical lupin plant use unrelated
lupin.com·1d ago·HR AI topic irrelevant to pharma
TipRanks·1d ago·pivot signals reduced lupin ingredient demand
Business Upturn·2d ago·pharma index gains lift Lupin slightly
BioWorld News·5d ago·NMPA nod and spinoff indicate progress
MarketsMojo·5d ago·open interest surge with mixed pricing
Equitypandit·5d ago·weekly outlook note neutral timing
Business Upturn·5d ago·Lupin shares decline in pharma drop
Mshale·6d ago·stock watchlist mention only
Entertainment.ie·6d ago·Harry Potter unrelated to company
The Pharma Letter·6d ago·oncology spinout may unlock value
CNBC TV18·6d ago·fake medicine seizure harms brand
dars.gov.et·6d ago·tariff concerns weigh on earnings
dars.gov.et·6d ago·pharma slide reflects weak earnings
dars.gov.et·6d ago·tariff worries hurt pharma earnings
dars.gov.et·7d ago·pharma slip tied to earnings concerns
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
26.62 vs 23.20535
14.71% surprise
| 9.93% |
| 14.94% |
| 5.60% |
| CIPLA | 1.19T | 35.31 | — | 12.55% | 3.50% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹2,402.00
Resistance (day/52w high)
₹2,463.00
Volume
11,39,237
Trend
up
RSI (14)
44
MACD
bearish
MA cross
golden
50-day MA
₹2,360.33
200-day MA
₹2,230.87
vs 200-DMA
9.7%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.